OCC 2.63% 39.0¢ orthocell limited

Ann: Strategic Placement to Raise $3.5 million, page-33

  1. 7,600 Posts.
    lightbulb Created with Sketch. 6869
    Georgie...that's what I am saying. I will be dropping the Chair an e-mail. No discount placements unless its an involved business partner. They don't need the cash. We don't want the register strengthened via this route - and importantly its not what he guided at the AGM.

    They are amply funded to Remplir FDA approval and US mkt entry. Take out the R&D they are already cash flow positive. Once they have Remplir in US mkts, along with existing Straite sales (and Remplir AU sales) they will very soon likely be cash flow positive on what remaining R&D they have getting ATI and CelGro Tendon to mkt.

    JVDW needs a little reminder of his ultimate main stakeholders => shareholders beyond insiders.
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
39.0¢
Change
0.010(2.63%)
Mkt cap ! $81.73M
Open High Low Value Volume
38.0¢ 39.0¢ 38.0¢ $30.42K 78.69K

Buyers (Bids)

No. Vol. Price($)
2 54528 38.0¢
 

Sellers (Offers)

Price($) Vol. No.
39.0¢ 183416 3
View Market Depth
Last trade - 16.10pm 05/09/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.